Phase II Open-label, Multi-center Study of Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma (mUM) With Integrated Circulating Tumor DNA (ctDNA) Biomarker (TARGET-tebe)

16103HCC-22-165-NCT06070012OpenPhase II Open-label, Multi-center Study of Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma (mUM) With Integrated Circulating Tumor DNA (ctDNA) Biomarker (TARGET-tebe)HCC-22-165NCT06070012InstitutionalAdultTreatmentIIMelanoma, SkinRapisuwon, SutheeGeorgetown University Medical Center : Beth Mekonen; Lombardi Comprehensive Cancer Center : Beth MekonenMelanomaOncology GroupLombardi Comprehensive Cancer Center (LCCC); Oncology PFS16061Beth MekonenBeth Mekonenbam159@georgetown.edu2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>